[Clinical studies on cefminox in pediatric field]

Area of Science:

• Pharmacology
• Infectious Diseases
• Clinical Microbiology

Context:

• Bacterial infections pose a significant global health challenge, necessitating the development of effective antimicrobial agents.
• Cefminox (CMNX) is a novel antibiotic investigated for its therapeutic potential.
• Understanding the pharmacokinetic and pharmacodynamic properties of CMNX is crucial for its clinical application.

Purpose:

• To evaluate the clinical efficacy and safety of cefminox (CMNX) in treating bacterial infections.
• To assess the antibacterial activity of CMNX against common human pathogens.
• To determine the pharmacokinetic profile of CMNX, including serum concentrations, half-life, and urinary excretion.

Summary:

• Clinical trials involving twelve patients with bacterial infections showed that cefminox (CMNX) achieved an "excellent" success rate in 9 cases and a "good" rate in 3.
• In vitro studies demonstrated CMNX's potent activity against key pathogens such as Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae, with complete eradication observed in all treated cases.
• Pharmacokinetic analysis revealed dose-dependent serum concentrations, with mean maximum concentrations ranging from 54.5 to 202.4 mcg/ml after intravenous administration. Mean half-lives were approximately 1.13-1.60 hours, and urinary excretion rates at 6 hours post-injection varied between 66.5% and 92.6%.

Impact:

• Cefminox (CMNX) shows promise as a safe and effective antibiotic for treating a range of bacterial infections.
• The favorable pharmacokinetic profile suggests potential for convenient dosing regimens.
• Further research may establish CMNX as a valuable therapeutic option in combating antimicrobial resistance.